BioNTech (BNTX) Stock Price, News & Analysis

+1.20 (+1.38%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
528,474 shs
Average Volume
680,192 shs
Market Capitalization
$20.92 billion
P/E Ratio
Dividend Yield
Price Target

BioNTech MarketRank™ Stock Analysis

Analyst Rating
2.30 Rating Score
36.8% Upside
$120.40 Price Target
Short Interest
1.30% of Float Sold Short
Dividend Strength
News Sentiment
0.74mentions of BioNTech in the last 14 days
Based on 11 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($1.73) to ($1.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.49 out of 5 stars

Medical Sector

265th out of 909 stocks

Biological Products, Except Diagnostic Industry

39th out of 154 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
BioNTech (NASDAQ:BNTX) Given "Buy" Rating at HC Wainwright
Assessing BioNTech: Insights From 11 Financial Analysts
The 3 Best Bargain Stocks to Buy in Q2 2024
Don’t Miss Out on the AI Gold Rush That’s Just Getting Started
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
BioNTech Full Year 2023 Earnings: Misses Expectations
BioNTech Q4 Net Profit Plummets
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
10 Analysts


Net Income
$1.01 billion
Pretax Margin


Sales & Book Value

Annual Sales
$4.13 billion
Cash Flow
$5.17 per share
Book Value
$92.17 per share


Free Float
Market Cap
$21.03 billion

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ugur Sahin M.D. (Age 59)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $1.23M
  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $809.78k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $1.42M
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $832.18k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $1.02M
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $803.38k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
    Comp: $601.73k
  • Mr. Zach Taylor
    Senior Vice President of Corporate Development & Strategy
  • Dr. Katalin Kariko Ph.D.
    Senior VP & External Consultant for RNA Protein Replacement Therapies
  • Dr. Oliver Henning Ph.D.
    Senior Vice President of Operations

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained


Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech SE is actively developing a range of innovative immunotherapies for cancer and infectious diseases, showcasing a strong pipeline of product candidates.
  • The company's FixVac product candidates, such as BNT122 in Phase II clinical trials for first-line melanoma and multiple solid tumors, demonstrate promising potential in addressing unmet medical needs.
  • BioNTech SE has established collaborations with reputable partners like Genentech, Pfizer, and Sanofi, enhancing its research capabilities and market reach.
  • With ongoing clinical trials for various cancers like prostate, ovarian, and lung cancer, BioNTech SE is positioned to make significant advancements in cancer treatment, potentially leading to increased market value.
  • Considering the current stock price and the company's robust development pipeline, investing in BioNTech SE could offer long-term growth opportunities for investors.


Investors should be bearish about investing in BioNTech SE for these reasons:

  • Despite the promising pipeline, the biotechnology industry is highly competitive and subject to regulatory challenges, which could impact the company's ability to bring products to market successfully.
  • Ongoing clinical trials carry inherent risks, including potential setbacks or failures, which could lead to delays in product approvals and revenue generation.
  • The success of BioNTech SE's product candidates is not guaranteed, and any setbacks in clinical trials or regulatory approvals could negatively affect the company's financial performance and stock value.
  • Investing in biotechnology companies like BioNTech SE involves high volatility due to market sentiment, regulatory changes, and scientific uncertainties, which may not align with all investors' risk tolerance levels.
  • While the company has collaborations with industry leaders, partnership dynamics and outcomes are subject to change, impacting BioNTech SE's research priorities and market positioning.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these BioNTech pros and cons to

BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price target for 2024?

10 brokerages have issued twelve-month target prices for BioNTech's stock. Their BNTX share price targets range from $90.00 to $171.00. On average, they predict the company's stock price to reach $120.40 in the next year. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2024?

BioNTech's stock was trading at $105.54 on January 1st, 2024. Since then, BNTX shares have decreased by 16.6% and is now trading at $88.01.
View the best growth stocks for 2024 here

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our BNTX earnings forecast

How can I listen to BioNTech's earnings call?

BioNTech will be holding an earnings conference call on Monday, May 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) released its earnings results on Wednesday, March, 20th. The company reported $2.05 earnings per share for the quarter, missing analysts' consensus estimates of $2.64 by $0.59. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a trailing twelve-month return on equity of 4.60%.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an initial public offering (IPO) on Thursday, October 10th 2019. The company issued 13,200,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include IMC Chicago LLC (0.00%), Legacy Wealth Asset Management LLC (0.00%), Green Alpha Advisors LLC (0.00%), Wealthcare Advisory Partners LLC (0.00%), Park Avenue Securities LLC (0.00%) and American National Bank (0.00%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 4/23/2024 by Staff

From Our Partners